Perspectives and Presentations From Expert Practice in PCA - priME Oncology
Expert Perspectives
Expert Perspectives

Perspectives and Presentations From Expert Practice in PCA

Maximizing Patient Care With Innovation and Collaboration

Not a member of My prIME? Join now for instant access.

View expert perspective videos and downloadable slides from our 1.5-day live meeting addressing the treatment of patients with PCA. This activity will help to enhance your understanding of PCA in order to provide optimal treatment strategies using standard as well as new/emerging agents.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Oct 22, 2018

Expiration Date

Oct 22, 2019

Chairs

  • Philip Agop Philip, MD, PhD, FRCPWayne State University and Karmanos Cancer Institute
    Detroit, Michigan, United States
  • Thomas Seufferlein, MD, PhD University of Ulm
    Ulm, Germany
  • Eric Van Cutsem, MD, PhDUniversity Hospitals Leuven
    Leuven, Belgium

Faculty

  • Matti Aapro, MDMultidisciplinary Oncology Institute
    Genolier, Switzerland
  • Maria Antonietta Bali, MD, PhDInstitut Jules Bordet
    Free University of Brussels
    Brussels, Belgium
  • Thomas Brunner, MD, PhDUniversity Medical Center Freiburg
    Freiburg, Germany
  • Stefano Cascinu, MD, PhDUniversity of Modena and Reggio Emilia
    Modena, Italy
  • Massimo Falconi, MDUniversity Vita-Salute San Raffaele
    IRCCS San Raffaele Hospital
    Milan, Italy
  • Teresa Macarulla, MD, PhDVall d’Hebron University Hospital
    Barcelona, Spain
  • Gerald Prager, MDMedical University of Vienna
    Vienna, Austria

Introduction

PCA management: Why is it so challenging?
Gerald Prager, MD     

Improving Outcomes in Patients With Resectable/Borderline Resectable PCA

Contemporary management of resectable/borderline resectable PCA: Surgery or neoadjuvant therapy first?
Massimo Falconi, MD

Optimizing adjuvant therapy in PCA: Impact of new data
Eric Van Cutsem, MD, PhD

Multimodality Treatment of Locally Advanced PCA

Systemic therapy for locally advanced PCA
Stefano Cascinu, MD, PhD

Update on locoregional treatment approaches for PCA
Thomas Brunner, MD

Supportive care measures throughout the patient’s cancer journey
Matti Aapro, MD 

Fine-Tuning Continuum of Care in Metastatic Pancreatic Cancer (mPCA) 

Individualizing systemic therapy for mPCA across the disease continuum
Teresa Macarulla, MD, PhD  

Targeted therapy in mPCA: Are we moving forward?
Philip Agop Philip, MD, PhD, FRCP

prIME Points™ and what to expect in PCA management in the coming years
Thomas Seufferlein, MD, PhD

This educational activity is designed for European gastroenterologists, surgical, radiation, and medical oncologists, and other healthcare providers involved in the management of patients with pancreatic cancer (PCA).

After successful completion of this educational activity, participants should be able to:

  • Identify risk factors for PCA and discuss reasons for poor outcomes and treatment resistance, including genetic diversity and role of PCA stroma
  • Recognize imaging criteria for resectability of PCA
  • Establish and implement multimodality treatment strategies for resectable, borderline resectable, and unresectable/locally advanced PCA, and discuss the importance of a multidisciplinary team approach
  • Select the most appropriate therapy for individual patients with metastatic pancreatic ductal adenocarcinoma in the first-line setting and beyond progression
  • Assess supportive care measures to ameliorate disease symptoms and treatment-related adverse events throughout the course of PCA management
  • Describe the potential role of genomic profiling and evaluate novel treatment approaches in PCA including targeted therapy for DNA repair defects, stromal targeting agents, agents targeting abnormal metabolism in PCA cells, and immunotherapeutic strategies

This educational activity is supported by grants from Celgene, ERYTECH, RAFAEL Pharmaceuticals, and Shire.

ENDURING MATERIALS FROM A CERTIFIED ACTIVITY

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Aapro has disclosed that he has received grants or research support from Helsinn and Pierre Fabre. He also disclosed receiving consulting fees from Amgen, Bristol-Myers Squibb, Celgene, Clinigen, Eisai, Genomic Health, GlaxoSmithKline, Helsinn, Hospira, Johnson & Johnson, Novartis, Merck, Merck Serono, Mundipharma, Pfizer, Pierre Fabre, Roche, Sandoz, Tesaro, Teva, and Vifor. He further disclosed receiving honoraria for lectures at symposia from Amgen, Bayer Schering, Cephalon, Chugai, Eisai, Genomic Health, GlaxoSmithKline, Helsinn, Hospira, Ipsen, Johnson & Johnson, OrthoBiotech, Kyowa Hakko Kirin, Merck, Merck Serono, Mundipharma, Novartis, Pfizer, Pierre Fabre, Roche, Sandoz, Sanofi, Tesaro, Taiho, Teva, and Vifor. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Bali has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Brunner has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Cascinu has disclosed that he has received grants or research support from Celgene. He has also received honoraria or consultation fees from Celgene. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Falconi has disclosed participation in company-sponsored speaker’s bureaus for Advanced Accelerator Applications, Celgene, Ipsen, Johnson & Johnson, and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Macarulla has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Prager has disclosed that he has received honoraria from Celgene, Halozyme, Servier, and Shire. He has also participated in advisory boards for Celgene, Halozyme, Servier, and Shire. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Philip has disclosed that he has received grants or research support from Celgene and Merck. He has also received honoraria or consultation fees from Celgene and Ipsen. Dr Philip has also disclosed participation in company-sponsored speaker’s bureau for Celgene and Ipsen. He has further disclosed that he is a stock shareholder in RAFAEL Pharmaceuticals. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Seufferlein has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Van Cutsem has disclosed that he has received grants or research support from Amgen, Bayer, Bristol-Myers Squibb, Boehringer, Celgene, Ipsen, Lilly, Merck, Merck KgA, Novartis, Roche, and Servier. He has also received honoraria or consultation fees from Bayer, Bristol-Myers Squibb, Celgene, Lilly, Merck, Merck KgA, Novartis, and Servier. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Bojana Pajk, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Sanneke Koekkoek, RN (scientific content reviewer/planner) – no relevant financial relationships
  • Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.